{"product_id":"phospho-polr2a-antibody-ps2-bha17109316","title":"Phospho-POLR2A Antibody (pS2)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003ePhospho-POLR2A Antibody (pS2) is a research-use antibody directed against \u003cstrong\u003ePHOSPHO-POLR2A\u003c\/strong\u003e. It is supplied for use in common immunoassay contexts such as WB (RUO).\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e PHOSPHO-POLR2A.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eDescription (provided):\u003c\/strong\u003e DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eAntibody type:\u003c\/strong\u003e Rabbit, clone AH-16, Rabbit IgG.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified; Protein A affinity.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eReported\/predicted localization:\u003c\/strong\u003e Nucleus.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e tested: Human.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eImmunogen (if provided):\u003c\/strong\u003e The amino acids surrounding phosphorylated Serine at position 2 were used as the immunogen for the phospho-POLR2A antibody..\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe information above helps you match the antibody format to your assay context, interpret species-dependent differences, and anticipate how epitope context (isoforms, PTMs, or conformational state) may influence signal.\u003c\/p\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eDNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single-stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Acts as an RNA- dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicate and transcriptase for the viral RNA circular genome. .\u003c\/p\u003e\n\u003cp\u003eFor curated annotations (gene\/protein naming, domains, isoforms, and pathway links) for PHOSPHO-POLR2A, consult primary databases such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e\n\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eContext-dependent expression studies: researchers often examine PHOSPHO-POLR2A abundance and localization across perturbations (genetic, pharmacologic, or environmental) to connect phenotype to molecular changes.\u003c\/li\u003e  \u003cli\u003eReagent reproducibility: there is growing emphasis on antibody specificity checks using orthogonal approaches (e.g., genetic perturbation or independent antibodies) and transparent reporting of clone\/lot information.\u003c\/li\u003e  \u003cli\u003eMulti-modal datasets: antibody-based readouts are increasingly combined with transcriptomics and imaging to relate protein-level measurements to cell-state transitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eWestern blotting (immunoblot) for relative detection of target protein abundance and apparent molecular weight.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen comparing conditions, interpret changes in signal in the context of sample composition, expected localization, and any known isoform complexity for the target.\u003c\/p\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e alternative splicing or post-translational modifications can change epitope accessibility and apparent molecular weight; interpret bands\/signals accordingly.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eCross-reactivity and matrix effects:\u003c\/strong\u003e background binding can vary by sample type, species, and blocking\/detection chemistries; include appropriate negative controls.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e where feasible, use genetic perturbation (KO\/KD\/overexpression), orthogonal assays, or independent antibodies to support specificity claims.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAntibody considerations:\u003c\/strong\u003e Polyclonal reagents may recognize multiple epitopes and can increase sensitivity but may show broader binding profiles, while monoclonal clones provide a single-epitope readout that can improve consistency across experiments. If a conjugate is listed, the antibody supports more direct detection workflows; otherwise, it is typically used with a compatible secondary antibody.\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProtKB entry for PHOSPHO-POLR2A (UniProt): https:\/\/www.uniprot.org\/uniprotkb\/P24928\n- NCBI Gene search for PHOSPHO-POLR2A (NCBI): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=PHOSPHO-POLR2A\n- Ensembl gene search for PHOSPHO-POLR2A (Ensembl): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=PHOSPHO-POLR2A\n- Antibody validation “5 pillars” (Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995\n- NIH replication \u0026 reproducibility resources (NIH): https:\/\/www.nih.gov\/replicationandreproducibility\n- Human Protein Atlas search for PHOSPHO-POLR2A (HPA): https:\/\/www.proteinatlas.org\/search\/PHOSPHO-POLR2A\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"Antibody in PBS with 0.02% sodium azide, 50% glycerol and 0.4-0.5mg\/ml BSA \/ 100 ul","offer_id":53044471398765,"sku":"RQ4505","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_cc2e4071-7418-4540-bd3a-84a9500bab6f.jpg?v=1771938913","url":"https:\/\/www.ebiohippo.com\/products\/phospho-polr2a-antibody-ps2-bha17109316","provider":"BioHippo","version":"1.0","type":"link"}